OmniAb, Inc. (OABI) Investor Relations Documents

OmniAb, Inc. (OABI) investor relations documents from the company's IR site: 3 presentations, 32 press releases; latest deck 2026-05-07. Read in-app with summaries. First-party data.

Presentation of Q1 2026, PDF file, (opens in new window): OmniAb's Q1 2026 results show $14.4M revenue and a narrowed net loss. The company raised its 2026 revenue guidance to $28-33M, driven by advancements in its partner pipeline and

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-17Press releaseOmniAb Raises 2026 Financial Guidance
2026-08-17Press releaseOmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
2026-08-06Press releaseOmniAb to Report Second Quarter 2026 Financial Results on August 6
2026-08-06Press releasePress Release
2026-07-13Press releaseOmniAb Names Amechi Nwachuku Chief Operating Officer
2026-05-07Press releasePress Release
2026-05-07Press releaseOmniAb to Report First Quarter 2026 Financial Results on May 7
2026-05-07Earnings deckPresentation of Q1 2026, PDF file, (opens in new window)
2026-03-08Press releaseOmniAb to Participate at the Leerink Partners Global Healthcare Conference
2026-03-04Press releasePress Release
2026-03-04Press releaseOmniAb to Report Fourth Quarter 2025 Financial Results on March 4
2025-12-15Press releaseLaunch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery
2025-12-15Press releaseOmniAb to Hold OmniUltra Virtual Investor Event on December 15
2025-11-19PresentationPresentation
2025-11-17Press releaseOmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Comp
2025-11-03Quarterly reportQ3 2025 Financial Results & Business Update call
2025-11-04Press releaseOmniAb to Report Third Quarter 2025 Financial Results on November 4
2025-10-16Press releaseOmniAb to Participate in Three Investor Conferences in November
2025-08-25Press releaseOmniAb Announces $30 Million Private Placement
2025-08-05Quarterly reportQ2 2025 Financial Results & Business Update call
2025-08-06Quarterly reportQuarterly Filing
2025-08-06Press releaseOmniAb to Report Second Quarter 2025 Financial Results on August 6
2025-05-13Press releaseOmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston
2025-05-08Quarterly reportQ1 2025 Financial Results & Business Update earnings call
2025-05-08Press releaseOmniAb to Report First Quarter 2025 Financial Results on May 8
2025-05-08Press releaseOmniAb Introduces the xPloration® Partner Access Program
2025-05-01Press releaseOmniAb to Participate in Five Upcoming Investor Conferences
2025-04-21Press releaseOmniAb Announces Two New Appointments to its Board of Directors
2025-03-18Quarterly reportQ4 2024 Financial Results & Business Update earnings call
2025-03-18Press releaseOmniAb to Report Fourth Quarter 2024 Financial Results on March 18
2025-02-03Press releaseOmniAb to Participate in Two Investor Conferences in March
2024-12-16Press releaseOmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
2024-11-12Press releaseOmniAb to Report Third Quarter 2024 Financial Results on November 12
2024-11-12Press releaseOmniAb Reports Third Quarter 2024 Financial Results and Business Highlights
2024-11-12Press releasePress Release
2024-10-30Press releaseOmniAb to Participate in Two Investor Conferences in November
2024-08-26Press releaseOmniAb to Participate in Two Investor Conferences in September
2024-08-08Press releaseOmniAb to Report Second Quarter 2024 Financial Results on August 8
2024-08-08PresentationPresentation
2024-08-08Press releasePress Release

OABI overview · OABI earnings · OABI financials · OABI KPIs · OABI documents · OABI ownership · OABI peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.